注射用骨肽联合阿仑膦酸钠治疗骨质疏松症的临床研究  

Clinical research of bone peptide for injection combined with alendronate treatment for osteoporosis

作　　者：孟晓林[1] 马东亚[1] 王春[1] 白亮[1] 李扬[1] 陈诚[1] 

机构地区：[1]阜阳市第二人民医院骨科,安徽阜阳236015

出　　处：《实用药物与临床》2012年第8期490-491,共2页Practical Pharmacy and Clinical Remedies

摘　　要：目的探讨注射用骨肽联合阿仑膦酸钠治疗骨质疏松症的临床疗效。方法将128例骨质疏松症患者随机分入对照组与观察组,对照组患者给予阿仑膦酸钠片联合钙尔奇D治疗,观察组患者给予骨肽、阿仑膦酸钠及钙尔奇D治疗。比较两组患者临床疗效及治疗前后前臂骨密度、骨矿含量的改变。结果观察组与对照组临床治疗总有效率分别为92.4%和74.2%,差异具有统计学意义(P<0.05);治疗前两组前臂近端骨密度(PBD)、近端骨矿含量(PBMC)、远端骨密度(DBD)和远端骨矿含量(DBMC)差异无统计学意义,治疗后6个月观察组上述指标显著优于对照组(P<0.05)。结论注射用骨肽联合阿仑膦酸钠治疗骨质疏松症可显著增加骨密度,临床疗效确切。Objective To explore the clinical efficacy of bone peptide for infection combined with alendronate treatment for osteoporosis.Methods 128 cases with osteoporosis were randomly divided into control group and treatment group.Control group were given alendronate combined with caltrate-D treatment,and treatment group received peptide,alendronate and caltrate-D treatment.Clinical efficacy,bone mineral density and bone mineral content of forearm before and after treatment were compared between the two groups.Results The effective rates were 92.4% and 74.2% in experience group and control group respectively（P0.05）;There was no significant difference in PBD,PBMC,DBD and DBMC before treatment between the two groups（P0.05）,while these indexes in experience group were superior to control group after treatment（P0.05）.Conclusion Bone peptide for injection combined with alendronate can increase bone mineral density in patients with osteoporosis,and it has good efficacy.

关 键 词：骨质疏松症 骨肽 阿仑膦酸钠 

分 类 号：R580[医药卫生—内分泌]